Research programme: anti-viral therapeutics - US Phytotherapy

Drug Profile

Research programme: anti-viral therapeutics - US Phytotherapy

Alternative Names: PROACT D; PROACT-Z

Latest Information Update: 26 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator US Phytotherapy
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chikungunya virus infections; Dengue; Malaria; Yellow fever; Zika virus infection

Most Recent Events

  • 24 Aug 2016 US Phytotherapy announces intention to file IND to US FDA for Dengue
  • 24 Aug 2016 US Phytotherapy plans phase I trials for Dengue in USA
  • 20 Apr 2016 Preclinical trials in Chikungunya virus infections, Dengue, Malaria, Yellow fever, Zika virus infection in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top